[Federal Register Volume 61, Number 66 (Thursday, April 4, 1996)]
[Notices]
[Page 15121]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 96-8309]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Manufacturer of Controlled Substances; Notice of Application
Pursuant to Section 1301.43(a) of Title 21 of the Code of Federal
Regulations (CFR), this is notice that on January 31, 1996, Radian
Corporation, P.O. Box 201088, 8501 Mopac Blvd., Austin, Texas 78720,
has made written request to the Drug Enforcement Administration (DEA)
for registration as a bulk manufacturer of the basic classes of
controlled substances listed below:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Cathinone (1235)........................................... I
Methcathinone (1237)....................................... I
N-Ethylamphetamine (1475).................................. I
N,N-Dimethylamphetamine (1480)............................. I
Aminorex (1585)............................................ I
4-Methylaminorex (cis isomer) (1590)....................... I
Methaqualone (2565)........................................ I
Lysergic acid diethylamide (7315).......................... I
Tetrahydrocannabinols (7370)............................... I
Mescaline (7381)........................................... I
3,4-Methylenedioxyamphetamine (7400)....................... I
3,4-Methylenedioxy-N-ethylamphetamine (7404)............... I
3,4-Methylenedioxymethamphetamine (7405)................... I
4-Methoxyamphetamine (7411)................................ I
Psilocybin (7437).......................................... I
Psilocyn (7438)............................................ I
Dihydromorphine (9145)..................................... I
Normorphine (9313)......................................... I
Acetylmethadol (9601)...................................... I
Alphacetylmethadol except Levo-Alphacetylmethadol (9603)... I
Normethadone (9635)........................................ I
3-Methylfentanyl (9813).................................... I
Amphetamine (1100)......................................... II
Methamphetamine (1105)..................................... II
Methylphenidate (1724)..................................... II
Amobarbital (2125)......................................... II
Pentobarbital (2270)....................................... II
Secobarbital (2315)........................................ II
Phencyclidine (7471)....................................... II
1-Piperidinocyclohexanecarbonitrile (8603)................. II
Dihydrocodeine (9120)...................................... II
Oxycodone (9143)........................................... II
Hydromorphone (9150)....................................... II
Diphenoxylate (9170)....................................... II
Benzoylecgonine (9180)..................................... II
Ethylmorphine (9190)....................................... II
Hydrocodone (9193)......................................... II
Isomethadone (9226)........................................ II
Meperidine (9230).......................................... II
Methadone (9250)........................................... II
Methadone-intermediate (9254).............................. II
Morphine (9300)............................................ II
Levo-alphacetylmethadol (9648)............................. II
Oxymorphone (9652)......................................... II
Alfentanil (9737).......................................... II
Sufentanil (9740).......................................... II
Fentanyl (9801)............................................ II
------------------------------------------------------------------------
The firm plans to manufacture small quantities of the listed
controlled substances to make drug reference standards.
Any other such applicant and any person who is presently registered
with DEA to manufacture such substances may file comments or objections
to the issuance of the above application.
Any such comments or objections may be addressed, in quintuplicate,
to the Deputy Assistant Administrator, Office of Diversion Control,
Drug Enforcement Administration, United States Department of Justice,
Washington, D.C. Federal Register Representative (CCR), and must be
filed no later than June 3, 1996.
Dated: March 27, 1996.
Gene R. Haislip,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 96-8309 Filed 4-3-96; 8:45 am]
BILLING CODE 4410-09-M